EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution

Sushma Krishnan, Letao Ma, Wei He, Weiyuan Hu, Ki Baek Lee, Qin Zhang, Ru-Rong Ji, Xinli Liu, Xin Ge

Antibody Therapeutics · 24.08.2026

DOI: 10.1093/abt/tbag044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 24.08.2026. Verfasst von Sushma Krishnan und 8 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Neurological Disorders and Stroke, Department of Defense.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Besides required biochemical and biological functions, suitable biophysical characteristics or developability are critical for the success of monoclonal antibody (mAb) therapeutics. Aiming to develop disease-modifying therapeutics for diabetic peripheral neuropathy (DPN), this study applied protein engineering strategies to improve the developability of an matrix metalloproteinase-9 inhibitory mAb.

Methods

A miniature diversity was introduced to replace two hydrophobic residues in CDR-H3. Following mAb production, comprehensive panels of biochemical and biophysical properties were measured. The optimized mutant was further validated by pharmacokinetics and in vivo efficacy studies.

Results

The optimized mutant exhibited favorable developability properties while retaining its biochemical activities, including high production yield, colloidal stability, nanomolar binding affinity and inhibition potency, exclusive selectivity, no nonspecific binding, proteolytic resistance, cross-species activity, and thermostability. Furthermore, the optimized mAb demonstrated remarkably improved pharmacokinetics and significantly prolonged therapeutic effects in a mouse model of DPN.

Conclusions

Given the critical role of developability in mAb therapeutics, this study highlights a practical strategy for improving both developability and in vivo efficacy through rational site-directed mutagenesis.

Förderung

  • National Institute of Neurological Disorders and Stroke
  • Department of Defense

Zitieren

APA

Krishnan, S., Ma, L., He, W., Hu, W., Lee, K. B., Zhang, Q., Ji, R., Liu, X., & Ge, X. (2026). Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag044

Vancouver

Krishnan S, Ma L, He W, Hu W, Lee KB, Zhang Q, et al. Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag044

BibTeX
@article{Krishnan2026,
  author = {Krishnan, Sushma and Ma, Letao and He, Wei and Hu, Weiyuan and Lee, Ki Baek and Zhang, Qin and Ji, Ru-Rong and Liu, Xinli and Ge, Xin},
  title = {Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution},
  journal = {Antibody Therapeutics},
  year = {2026},
  doi = {10.1093/abt/tbag044}
}
Kostenlos starten →